PRODUCT INFORMATION Carmustine Item No

PRODUCT INFORMATION Carmustine Item No. 15775

CAS Registry No.: 154-93-8 Formal Name: N,N’-bis(2-chloroethyl)-N-nitroso-urea Synonyms: BCNU, bis-Chloroethylnitrosourea, O Gliadel, NSC 409962 H N MF: C5H9Cl2N3O2 N N

FW: 214.1 Cl Cl Purity: ≥95% O Stability: ≥2 years at -20°C Supplied as: A crystalline solid UV/Vis.: λmax: 231 nm

Laboratory Procedures

For long term storage, we suggest that carmustine be stored as supplied at -20°C. It should be stable for at least two years. Carmustine is supplied as a crystalline solid. A stock solution may be made by dissolving the carmustine in the solvent of choice. Carmustine is soluble in organic solvents such as ethanol and DMSO, which should be purged with an inert gas. The solubility of carmustine in these solvents is approximately 100 mM. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of carmustine can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of carmustine in water is approximately 25 mM. We do not recommend storing the aqueous solution for more than one day.

Description

Carmustine is a nitrogen mustard β-chloro-nitrosourea compound that is used as an alkylating agent.1 It forms interstrand crosslinks in DNA, which prevents DNA replication and transcription leading to apoptosis.2 Carmustine is also reported to inhibit glutathione reductase, thioredoxin reductase, and lipoamide dehydrogenase.3 Carmustine has been tested in clinical trials as a cytostatic agent for Hodgkin’s and non-Hodgkin’s lymphoma, myeloma, malignant melanoma, glioblastoma, and other brain tumors.4

References

1. Burchenal, J.H. and Carter, S.K. New cancer chemotherapeutic agents. Cancer 30(6), 1639-1646 (1972). 2. Wasserman, T.H., Slavik, M., and Carter, S.K. Clinical comparison of the nitrosoureas. Cancer 36(4), 1258-1268 (1975). 3. Arscott, L.D., Gromer, S., Schirmer, R.H., et al. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase for Escherichia coli. Proc. Natl. Acad. Sci. USA 94, 3621-3626 (1997). 4. Zhang, Y.-D., Dai, R.-Y., Chen, Z., et al. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: A systematic review. Turk. Neurosurg. 24(5), 639-645 (2014).

WARNING CAYMAN CHEMICAL THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE. 1180 EAST ELLSWORTH RD SAFETY DATA ANN ARBOR, MI 48108 · USA This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. PHONE: [800] 364-9897

WARRANTY AND LIMITATION OF REMEDY [734] 971-3335 Buyer agrees to purchase the material subject to Cayman’s Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website. FAX: [734] 971-3640 [email protected] Copyright Cayman Chemical Company, 02/29/2016 WWW.CAYMANCHEM.COM